Proteins & Peptides
Synthetic peptide corresponding to a region of the neuraminidase N1 protein from seasonal Influenza A/Georgia/20/2006 (H1N1). Correspoding antibody I7650-04R recognizes region of the neuraminidase N1 protein from seasonal Influenza /Georgia/20/2006 (H1N1)._x000B__x000B_Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA (1). Novel influenza virus strains emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however it is in birds that all subtypes can be found (2). These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. During 1997, an H5N1 avian influenza virus was determined to be the cause of death in 6 of 18 infected patients in Hong Kong (3). There was some evidence of human to human spread of this virus, but it is thought that the transmission efficiency was fairly low (4). Although it has been known that cleavage site and glycosylation patterns of the HA protein play important roles in determining the pathogenicity of H5 avian influenza viruses, it has only recently been shown that an additional glycosylation site within the globular head of the NA protein also contributes to the high virulence of the H5N1 virus (5).
Antibody come from
Synthetic peptide corresponding to 14aa near the middle of the Hemagglutinin protein.
Provided as solution in phosphate buffered saline with 0.02% sodium azide. Purified
Antigen-antibody binding interaction
Influenza A Neuraminidase N1 (A/Georgia/20/2006) (H1N1) (Control peptide)
Antibody is raised in
Antibody's reacts with
Antibody's reacts with these species
This antibody doesn't cross react with other species
No Data Available
Antibody's suited for
Optimal concentration should be evaluated by serial dilutions.
no information yet
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
Isotype or positive controls by peptides, antibodies and deactivated samples.Influenza A and B H1N1 H3N2 Hemagglutinin-nucleoprotein recombinant proteins, peptides and antibodies detect a virus commonly known as "the flu". Influenza is an infectious disease caused by an influenza virus. Symptoms can be mild to severe. The most common symptoms include a high fever, runny nose, sore throat, muscle pains, headache, coughing, and feeling tired. These symptoms typically begin two days after exposure to the virus and most last less than a week. The cough, however, may last for more than two weeks. In children, there may be nausea and vomiting, but these are not common in adults.Peptides short amino acid chains or epitopes or blocking antagonists. The shortest peptides are dipeptides, consisting of 2 amino acids joined by a single peptide bond, followed by tripeptides, tetra peptides, ... till polypeptides that are long, continuous, and unbranched synthetic peptide chains. These biological oligomers and polymers can be Solid-phase peptide synthesis (SPPS), or in continue produced for custom peptide synthesis projects. The High-efficiency solid phase peptide synthesis (HE-SPPS) is give very low production costs.